Bicara therapeutics inc. common stockBCAX.US Overview

US StockHealthcare

(No presentation for BCAX)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

BCAX Overall Performance

BCAX AI Analysis & Strategy

BCAX Recent Performance

2.87%

Bicara therapeutics inc. common stock

0.81%

Avg of Sector

-1.14%

S&P500

BCAX PowerScanner

BCAX Key Information

BCAX Valuation Metrics

BCAX Earnings Table

BCAX Profile

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.